The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti- helicobacter pylori activity in vitro and in vivo

Molecules

Volumn 20, Issue 3, 2015, Pages 3972-3985

  Zhang, Xiao Lin ^a   Jiang, An Min ^b   Ma, Zhong You ^a   Li, Xian Bao ^a   Xiong, You Yi ^a   Dou, Jin Feng ^a   Wang, Jian Fei ^a,c  

^a ANHUI SCIENCE AND TECHNOLOGY UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c Ministry of Agriculture Key Laboratory of Microbial Organic Fertilizer   (China)

Author keywords

Antimicrobial peptide; Helicobacter pylori; Nanoparticles; Pexiganan

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; NANOPARTICLE; PEPTIDE; PEXIGANAN;

ANIMAL; DRUG EFFECTS; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; KINETICS; MALE; MICROBIOLOGY; MOUSE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; KINETICS; MALE; MICE; NANOPARTICLES; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84928390994     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20033972     Document Type: Article

References (39)

1. Fennerty, M.B.; Lieberman, D.A.; Vakil, N.; Magaret, N.; Faigel, D.O.; Helfand, M. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch. Intern. Med. 1999, 159, 1562-1566.
2. Osborn, J.F.; Cattaruzza, M.S.; Ferri, A.M.; de Angelis, F.; Renzi, D.; Marani, A.; Vaira, D. How long will it take to reduce gastric cancer incidence by eradicating Helicobacter pylori infection? Cancer Prev. Res (Phila) 2013, 6, 695-700.
3. Shah, S.; Qaqish, R.; Patel, V.; Amiji, M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J. Pharm. Pharmacol. 1999, 51, 667-672.
4. Lin, C.K.; Hsu, P.I.; Lai, K.H.; Lo, G.H.; Tseng, H.H.; Lo, C.C.; Peng, N.J.; Chen, H.C.; Jou, H.S.; Huang, W.K.; et al. One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. J. Clin. Gastroenterol. 2002, 34, 547-551.
5. Liou, J.M.; Chen, C.C.; Chen, M.J.; Chen, C.C.; Chang, C.Y.; Fang, Y.J.; Lee, J.Y.; Hsu, S.J.; Luo, J.C.; Chang, W.H.; et al. Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicenter, open-label, randomized trial. Lancet 2013, 381, 205-213.
6. Stenstroem, B.; Mendis, A.; Marshall, B. Helicobacter pylori: The latest in diagnosis and treatment. Aust. Fam. Phys. 2008, 37, 608-612.
7. Harris, M.; Mora-Montes, H.M.; Gow, N.A.; Coote, P.J. Loss of mannosyl-phosphate from Candida albicans cell wall proteins results in enhanced resistance to the inhibitory effect of a cationic antimicrobial peptide via reduced peptide binding to the cell surface. Microbiology 2009, 155, 1058-1070.
8. Bradshaw, J. Cationic antimicrobial peptides: Issues for potential clinical use. Bio Drugs 2003, 17, 233-240.
9. Peschel, A.; Sahl, H.G. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 2006, 4, 529-536.
10. Peters, B.M.; Shirtliff, M.E.; Jabra-Rizk, M.A. Antimicrobial peptides: Primeval molecules or future drugs? PLoS Pathog. 2010, 6, e1001067.
11. Brown, K.L.; Hancock, R.E. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 2006, 18, 24-30.
12. Diamond, G.; Beckloff, N.; Weinberg, A.; Kisich, K.O. The roles of antimicrobial peptides in innate host defense. Curr. Pharm. Des 2009, 15, 2377-2392.
13. Mader, J.S.; Hoskin, D.W. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert. Opin. Investig. Drugs 2006, 15, 933-946.
14. Mookherjee, N.; Hancock, R.E. Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci. 2007, 64, 922-933.
15. Steinstraesser, L.; Koehler, T.; Jacobsen, F.; Daigeler, A.; Goertz, O.; Langer, S.; Kesting, M.; Steinau, H.; Eriksson, E.; Hirsch, T. Host defense peptides in wound healing. Mol. Med. 2008, 14, 528-537.
16. Ge, Y.; MacDonald, D.L.; Holroyd, K.H.; Thornsberry, C.; Wexler, H.; Zasloff, M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 1999, 43, 782-788.
17. Nagahara, N.; Akiyama, Y.; Tada, M.; Nakao, M.; Kitano, M.; Ogawa, Y. Mucoadhesive microspheres containing amoxycillin for clearance of Helicobacter pylori . Antimicrob. Agents. Chemother. 1998, 42, 2492-2494.
18. Lin, Y.H.; Chang, C.H.; Wu, Y.S.; Hsu, Y.M.; Chiou, S.F.; Chen, Y.J. Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials 2009, 30, 3332-3342.
19. Patel, J.K.; Patel, M.M. Stomach specific anti-Helicobacter pylori therapy: Preparation and evaluation of amoxicillin loaded chitosan mucoadhesive microspheres. Curr. Drug. Deliv. 2007, 4, 41-50.
20. Ishak, R.A.H.; Awad, G.A.S.; Mortada, N.D.; Nour, S.A.K. Preparation, in vitro and in vivo evaluation of stomach specific metronidazole loaded alginate beads as local anti-Helicobacter pylori therapy. J. Control. Release 2007, 119, 207-214.
21. Lehr, C.M.; Bodde, H.E.; Bouwstra, J.A.; Junginger, H.E. A surface energy analysis of mucoadhesion. II. Prediction of mucoadhesive performance by spreading coefficients. Eur. J. Pharm. Sci 1993, 1, 19-30.
22. Deacon, M.P.; McGurk, S.; Roberts, C.J.; Williams, P.M.; Tendler, S.J.; Davies, M.C.; Davis, S.S.; Harding, S.E. Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem. J. 2000, 348, 557-563.
23. Peretz, A.; Paritsky, M.; Nasser, O.; Brodsky, D.; Glyatman, T.; Segal, S.; On, A. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults. J. Antibiot. (Tokyo) 2014, 67, 555-557.
24. Navon-Venezia, S.; Feder, R.; Gaidukov, L.; Carmeli, Y.; Mor, A. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob. Agents Chemother. 2002, 46, 689-694.
25. Radzishevsky, I.S.; Rotem, S.; Bourdetsky, D.; Navon-Venezia, S.; Carmeli, Y.; Mor, A. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. Biotechnol. 2007, 25, 657-659.
26. Eren, T.; Som, A.; Rennie, J.R.; Nelson, C.F.; Urgina, Y.; Nüsslein, K.; Coughlin, E.B.; Tew, G.N. Antibacterial and hemolytic activities of quaternary pyridinium functionalized polynorbornenes. Macromol. Chem. Phys. 2008, 209, 516-524.
27. Lamb, H.M.; Wiseman, L.R. Pexiganan Acetate. Drugs 1998, 56, 1047-1052.
28. Gottler, L.M.; Ramamoorthy, A. Structure, membrane orientation, mechanism, and function of pexiganan-a highly potent antimicrobial peptide designed from magainin. Biochim. Biophys. Acta 2009, 88, 1680-1686.
29. Hallock, K.J.; Lee, D.K.; Ramamoorthy, A. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys. J. 2003, 84, 3052-3060.
30. Dvinskikh, S.V.; Dürr, U.H.N.; Yamamoto, K.; Ramamoorthy, A. A high-resolution solid-state NMR approach for the structural studies of bicelles. J. Am. Chem. Soc. 2006, 128, 6326-6327.
31. Algood, H.M.S.; Cover, T.L. Helicobacter pylori persistence: An overview of interactions between H. pylori and host immune defenses. Clin. Microbiol. Rev. 2006, 19, 597-613.
32. Cuña, M.; Alonso, M.J.; Torres, D. Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxicillin-resin complexes for drug delivery to the gastric mucosa. Eur. J. Pharm. Biopharm. 2001, 51, 199-205.
33. Cooreman, M.P.; Krausgrill, P.; Hengels, K.J. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob. Agents Chemother. 1993, 37, 1506-1509.
34. Rajinikanth, P.S.; Balasubramaniam, J.; Mishra, B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. Int. J. Pharm. 2007, 335, 114-122.
35. Calvo, P.; Lopez, C.R.; Jato, J.L.C.; Alonso, M.J. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Poly. Sci. 1997, 63, 125-132.
36. Arora, S.; Gupta, S.; Narang, R.K.; Budhiraja, R.D. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. pylori. Sci. Pharm. 2011, 79, 673-694.
37. Akiyama, Y.; Nagahara, N.; Tashihara, T.; Morimoto, K.; Tabata, Y.; Ikada, Y. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm. Res. 1995, 12, 397-405.
38. Kleanthous, H.; Myers, G.A.; Georgakopoulos, K.M.; Tibbitts, T.J.; Ingrassia, J.W.; Gray, H.L.; Ding, R.; Zhang, Z.Z.; Lei, W.; Nichols, R.; et al. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immun. 1998, 66, 2879-2886.
39. Ferrero, R.L.; Thiberge, J.M.; Huerre, M.; Labigne, A. Immune responses of specific- pathogen-free mice to chronic Helicobacter pylori (strain SS1) infection. Infect. Immun. 1998, 66, 1349-1355.